# Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Canonical URL: https://biopharmsignal.com/news/CLDX/celldex-therapeutics-announces-closing-of-public-offering-of-common-stock-and-fu-cfb60edf
Ticker: CLDX
Company: Celldex Therapeutics
Source: Celldex Therapeutics
Published: 2026-04-06 14:53 EST
## Summary

Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of...

## Article Body
Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 11,896,750 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,551,750 shares of common stock at a public offering price of $29.00 per share. All of the shares sold in the offering were sold by Celldex. The gross proceeds to Celldex from this offering were approximately $345 million, excluding underwriting discounts and commissions and other offering-related expenses.

Leerink Partners, TD Cowen, Guggenheim Securities and Cantor acted as joint bookrunning managers for the offering. LifeSci Capital and H.C. Wainwright & Co. acted as co-lead managers for the offering.

The securities described above were offered and sold by Celldex pursuant to a shelf registration statement on Form S-3 (File No. 333-275300), which was previously filed with the Securities and Exchange Commission (“SEC”) and became automatically effective on November 3, 2023. This offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. The final terms of the offering are disclosed in a final prospectus supplement which has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov . Copies of the final prospectus supplement and the accompanying base prospectus may be obtained for free by contacting Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105 or by email at syndicate@leerink.com or TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com .

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Celldex

Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases.

Company Contact

Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration Celldex Therapeutics, Inc. (508) 864-8337 scavanaugh@celldex.com

Patrick Till Meru Advisors (484) 788-8560 ptill@meruadvisors.com

Source: Celldex Therapeutics, Inc.
## Recent Company News
- 2026-07-21 20:01 EST — [Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis](https://biopharmsignal.com/news/CLDX/celldex-reports-results-from-phase-2-study-of-barzolvolimab-in-prurigo-nodularis-3b2fe3ca) — Source: Celldex Therapeutics
- 2026-07-15 20:01 EST — [Celldex Announces Planned Transition of Chief Financial Officer](https://biopharmsignal.com/news/CLDX/celldex-announces-planned-transition-of-chief-financial-officer-26ce0227) — Source: Celldex Therapeutics
- 2026-06-14 14:21 EST — [Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting](https://biopharmsignal.com/news/CLDX/celldex-presents-long-term-barzolvolimab-results-demonstrating-sustained-off-tre-61dd564d) — Source: Celldex Therapeutics
- 2026-06-14 09:15 EST — [Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting](https://biopharmsignal.com/news/CLDX/celldex-presents-positive-first-in-human-results-from-phase-1-study-of-novel-bis-b70274b7) — Source: Celldex Therapeutics
- 2026-06-10 20:01 EST — [Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress](https://biopharmsignal.com/news/CLDX/celldex-announces-multiple-upcoming-presentations-from-leading-mast-cell-targeti-2a9c11f3) — Source: Celldex Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)